Last reviewed · How we verify

Levofloxacin oral tablets

GlaxoSmithKline · Phase 3 active Small molecule

Levofloxacin oral tablets is a Fluoroquinolone antibiotic Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Community-acquired pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis.

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis.

At a glance

Generic nameLevofloxacin oral tablets
SponsorGlaxoSmithKline
Drug classFluoroquinolone antibiotic
TargetDNA gyrase, Topoisomerase IV
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

As a fluoroquinolone antibiotic, levofloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA unwinding and replication. This dual inhibition leads to rapid bactericidal activity against a broad spectrum of gram-positive and gram-negative organisms, as well as atypical pathogens.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Levofloxacin oral tablets

What is Levofloxacin oral tablets?

Levofloxacin oral tablets is a Fluoroquinolone antibiotic drug developed by GlaxoSmithKline, indicated for Community-acquired pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis.

How does Levofloxacin oral tablets work?

Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.

What is Levofloxacin oral tablets used for?

Levofloxacin oral tablets is indicated for Community-acquired pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis, Uncomplicated skin and skin structure infections, Complicated urinary tract infections.

Who makes Levofloxacin oral tablets?

Levofloxacin oral tablets is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is Levofloxacin oral tablets in?

Levofloxacin oral tablets belongs to the Fluoroquinolone antibiotic class. See all Fluoroquinolone antibiotic drugs at /class/fluoroquinolone-antibiotic.

What development phase is Levofloxacin oral tablets in?

Levofloxacin oral tablets is in Phase 3.

What are the side effects of Levofloxacin oral tablets?

Common side effects of Levofloxacin oral tablets include Nausea, Diarrhea, Headache, Insomnia, Tendinitis/tendon rupture, QT prolongation.

What does Levofloxacin oral tablets target?

Levofloxacin oral tablets targets DNA gyrase, Topoisomerase IV and is a Fluoroquinolone antibiotic.

Related